Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how IPSEN (IPSEY) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $559.44, marking a +1.95% move from the previous day.
Why Is Thermo Fisher (TMO) Down 6.5% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana (HUM) Exits Business Line to Focus More on Core Units
by Zacks Equity Research
Humana (HUM) will depart from the Employer Group Commercial Medical Products business so that it can invest more funds to grow its core Insurance business lines.
Zacks.com featured highlights include Everest Re Group, Thermo Fisher Scientific and Sony Group
by Zacks Equity Research
Everest Re Group, Thermo Fisher Scientific and Sony Group are part of the Zacks Screen of the Week article.
3 Stocks With Sales Growth to Buy Amid Persistent Inflation
by Swayta Shah
Sales growth is vital for the survival of a business, even during an economic slowdown. Everest Re (RE), Thermo Fisher (TMO) and Sony Group (SONY) are recording top-line growth.
TMO vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. IDXX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser
by Zacks Equity Research
Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser are part of the Zacks top Analyst Blog.
Top Stock Reports for Merck, Thermo Fisher Scientific & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Thermo Fisher Scientific Inc. (TMO) and American Express Company (AXP).
Select Medical (SEM) Enters JV to Boost New Jersey Healthcare
by Zacks Equity Research
Select Medical (SEM) collaborates with AtlantiCare to open an inpatient rehabilitation hospital and jointly manage the operations of SEM's outpatient centers across New Jersey.
Thermo Fisher (TMO) Rides on Strong End Markets, New Launches
by Zacks Equity Research
Thermo Fisher's (TMO) newly-launched Gibco CTS DynaCellect Magnetic Separation System is helping customers advance their cell and gene therapy programs.
Encompass Health's (EHC) Shares Up 3% on Q4 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results reflect growing patient volumes and reimbursement rates. Management expects 2023 adjusted EPS within $2.87-$3.16, higher than $2.85 in 2022.
Catalent (CTLT) Surges on Rumors of Acquisition by Danaher
by Zacks Equity Research
Catalent (CTLT) shares gain significantly, following a Bloomberg report about a potential acquisition of the CDMO company by Danaher, a life sciences company.
Cigna (CI) Q4 Earnings Top on U.S. Commercial Unit, Dividend Up
by Zacks Equity Research
Cigna's (CI) fourth-quarter results reflect the strong contribution from the Evernorth segment. Management sanctions a 10% increase in the quarterly dividend.
Thermo Fisher (TMO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Thermo Fisher (TMO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Company News for Feb 2, 2023
by Zacks Equity Research
Companies in The News Are: ALGN, TMO, ATKR, WRK.
Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Robust year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments boost Thermo Fisher's (TMO) Q4 revenues.
Thermo Fisher (TMO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thermo Fisher Scientific (TMO) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.05% and 10.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Earnings on Feb 1: BSX, TMO & More
by Urmimala Biswas
Medical device companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, HOLX and ALGN fare this time.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $575.32 in the latest trading session, marking a -0.93% move from the prior day.
Earnings Preview: Thermo Fisher Scientific (TMO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
The industrywide trend of record-level inflation, supply issues and staffing shortages are expected to have deterred growth in several areas of Thermo Fisher's (TMO) business in Q4.
Beat the Market Like Zacks: Boeing, Starbucks, Syndax Pharma in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $583.86, moving +0.66% from the previous trading session.